Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Not pending/lapsed |
21 | DE file number | DAKZ | 601 48 467.3 |
96 | EP file number | EAKZ | 10 15 3374.3 |
97 | EP publication number | EPN | 2189162 |
54 | Designation/title | TI | Verfahren zur Behandlung der zellulären proliferativen Erkrankungen |
51 | IPC main class | ICM (ICMV) | A61K 35/76 (2006.01) |
22 | DE application date | DAT | Oct 26, 2001 |
96 | EP application date | EAT | Oct 26, 2001 |
43 | Date of first publication | OT | May 26, 2010 |
| Date of publication of grant | PET | Nov 27, 2013 |
71/73 | Applicant/owner | INH | Oncolytics Biotech, Inc., Calgary, Alberta, CA |
72 | Inventor | IN | Coffey, Matthew, C., Calgary, Alberta T2N 3L4, CA |
74 | Representative | VTR | VOSSIUS & PARTNER Patentanwälte Rechtsanwälte mbB, 81675 München, DE |
| Address for service | | VOSSIUS & PARTNER Patentanwälte Rechtsanwälte mbB, München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 246728 P Nov 9, 2000
|
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000002189162 Searchable text:
EP000002189162 Original document:
EP000002189162B1 Searchable text:
EP000002189162B1 |
43 | Date of first publication | EVT | May 26, 2010 |
| Date of the first transfer into DPMAregister | EREGT | May 27, 2011 |
| Date of the (most recent) update in DPMAregister | REGT | Oct 28, 2021 (Show all update days)(Hide all update days)- Oct 28, 2021; Oct 16, 2020; Oct 23, 2019; Oct 23, 2018; Oct 25, 2017; Nov 5, 2016; Nov 11, 2015; Nov 6, 2015; May 29, 2015; Dec 11, 2014; Nov 13, 2014; Nov 6, 2014; Nov 5, 2014; May 28, 2014; Jan 23, 2014; Dec 4, 2013; Nov 28, 2013; Nov 23, 2013; Feb 14, 2013
- Historical data not available for this/these date(s)
- May 27, 2011
- Date of the first transfer into DPMAregister
|